Overview

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
To assess and compare the efficacy and safety of ciprofloxacin extended-release (CIPRO XR) tablet 1000 mg PO once-daily (OD) versus ciprofloxacin immediate-release (CIPRO IR) tablet 500 mg PO twice-daily (BID) for 7-14 days in patients with complicated and/or nosocomial urinary tract infections (cUTI).
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Ciprofloxacin